Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic BK-specific cytotoxic T lymphocytes
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic BK-specific cytotoxic T lymphocytes (BKV-CTLs) are a cellular immunotherapy consisting of T cells specifically reactive to BK virus (BKV) that are derived from healthy donors. These cells are designed to restore antiviral immunity in immunocompromised patients suffering from BK virus reactivation. BKV-CTLs can be manufactured from partially HLA-matched third-party donors and stored as an "off-the-shelf" product for rapid administration. The therapy works by providing virus-specific T cells that can recognize and eliminate BKV-infected cells, helping to control viral replication and associated complications such as hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation.
02
Targets
JCV-pHLA (JC virus peptide-HLA complexes on infected cells)BKPyV (BK polyomavirus)
Beyond the preview
Go deeper on allogeneic BK-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic BK-specific cytotoxic T lymphocytes.